3rd-INCC

Session

Session 12

12

22 Sept 2011, 16:30

Città del Mare, Terrasini - Palermo - Sicily - Italy

201. Paving the way to personalized medicine: production of some theragnostic radionuclides at Brookhaven National Laboratory

Suresh C. Srivastava (Medical Department, Brookhaven National Laboratory, Upton, New York 11973, U.S.A.)

22/09/2011, 16:30

Radiopharmaceuticals Chemistry

oral presentation

This presentation will introduce a relatively novel paradigm that involves specific individual radionuclides or radionuclide pairs that have emissions that allow pre-therapy low-dose imaging plus higher-dose therapy in the same patient. We have made an attempt to sort out and organize a number of such theragnostic radionuclides and radionuclide pairs that may potentially bring us closer to the...

112. Cyclotron production of Sc-44 - new radionuclide for PET technique

Prof. Aleksander Bilewicz (Institute of Nuclear Chemistry and Technology)

22/09/2011, 16:50

Radiopharmaceuticals Chemistry

oral presentation

Objectives: Two isotopes of scandium, 47Sc and 44Sc, are perspective radionuclides respectively for radiotherapy and diagnostic imaging. 47Sc decays with the half-life of 3.35 days and maximum β- energy of 600 keV. It also emits low-energy γ-radiation (Eγ = 159 keV) suitable for simultaneous imaging. The other scandium radionuclide, 44Sc (t1/2 = 3.92h) is an ideal β+-emitter in PET diagnosis....

123. 99mTc(N)-DBODC(5) from cardiology to oncology: preliminary in vitro study

Prof. Alessandro Dolmella (University of Padova, Italy)

22/09/2011, 17:05

Radiopharmaceuticals Chemistry

oral presentation

99mTc(N)-DBODC(5) is a lipophilic cationic mixed-compound currently under clinical investigation as potential myocardial imaging agent. The findings that this complex accumulates in mitochondrial structures through a mechanism mediated by the negative mitochondrial membrane potential, and that the rapid efflux of 99mTc(N)-DBODC(5) from non-target tissues seems correlated to the Pgp/MDR-Pgp...